---
title: "FDA Requires Updating Ozempic and Wegovy Labels Due to Potential Vision Risks"
description: "The FDA is requiring label updates for Ozempic, Wegovy, and other GLP-1 medications due to a possible link with the rare eye condition NAION, which can cause vision loss."
date: 2026-11-16T11:08:30.675Z
lang: en
url: https://xab.info/en/posts/fda-requires-updating-ozempic-and-wegovy-labels
tags: [glp-1, ozempic, wegovy, fda, naion, weight-loss, vision-loss]
author: "Darya Fomina"
publisher: "XAB.info"
---

# FDA Requires Updating Ozempic and Wegovy Labels Due to Potential Vision Risks

![A woman in a white t-shirt administering a subcutaneous weight loss injection into her abdomen](https://xab.info/media/2026/11/16/fda-trebuet-obnovit-instruktsii-k-ozempic-i-wegovy/fda-trebuet-obnovit-instruktsii-k-ozempic-i-wegovy-1.webp)

## Key Points

- FDA requires adding NAION risk warnings to labels for Ozempic, Wegovy, Mounjaro, and Zepbound
- An analysis of 126 studies (over 134k participants) found 15 potential NAION cases: 10 in the GLP-1 group and 5 in controls
- The regulator stresses the link is potential, not proven; patients should consult a doctor if vision worsens

The U.S. Food and Drug Administration (FDA) has ordered manufacturers to update warnings in the labels of popular GLP-1 class medications used for type 2 diabetes and weight loss. According to Wave RBC.UA citing the regulator, the requirements apply specifically to Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound. The move was prompted by a clinical data review revealing a potential link between these drugs and a rare eye condition that can sometimes lead to irreversible vision loss.

### The Condition in Focus

The condition in question is non-arteritic anterior ischemic optic neuropathy (NAION), a rare disorder where blood flow to the optic nerve is disrupted. It is typically characterized by sudden, painless vision loss in one eye. In some cases, the vision loss is permanent, and if one eye is affected, there is a risk of the condition developing in the other eye as well. The FDA emphasizes that at this stage, the association between the medications and NAION is potential rather than a definitively proven cause-and-effect relationship.

### What Clinical Data Showed

The regulator's conclusions are based on an analysis of 126 clinical trials involving a total of more than 134,000 individuals. The analysis identified 15 potential cases of NAION: ten among patients taking GLP-1 class medications and five among those receiving placebo or other drugs. Scaled per 100,000 participants, the rate was 6.4 cases in the GLP-1 group versus 3.8 cases in the control group. This exact difference served as the basis for the labeling update requirement.

### What the FDA Demands from Manufacturers

The regulator has mandated that manufacturers include this information in the «Warnings and Precautions» section of the product labeling. Symptoms that patients should watch out for include sudden vision loss in one eye, dark spots, blurred vision, and altered color perception. If these symptoms occur, the FDA recommends seeking immediate medical attention while advising patients not to stop treatment on their own without consulting a specialist.

### Context: Next-Generation Drugs

Amid new warnings regarding the GLP-1 class, attention remains focused on retatrutide, an experimental weight-management drug being developed by Eli Lilly. This next-generation compound targets three hormone receptors simultaneously — GLP-1, GIP, and glucagon — which, according to the developers, helps control appetite, blood sugar levels, and body mass. As of November 2026, retatrutide remains an investigational drug awaiting regulatory approval.

## Fact-Check & Sources

- [Популярные препараты для похудения могут вызвать заболевание глаз: предупреждение FDA](https://wave.rbc.ua/ukr/wellness/populyarni-preparati-shudnennya-pov-yazali-1794826134.html) - Primary source: FDA requirement to update warnings for GLP-1 (Ozempic, Wegovy, Mounjaro, Zepbound), description of NAION, data from 126 studies (134+k participants, 15 cases, 6.4 vs 3.8 per 100k), retatrutide status as of November 2026.
- [Уколы для похудения преподнесли неприятный сюрприз: что выяснили в США](https://www.5-tv.ru/news/5094995/ukoly-dla-pokhudenia-prepodnesli-nepriatnyj-surpriz-cto-vyasnili-vssa/) - Independent confirmation: FDA warned about a potential link between GLP-1 RAs and NAION; matching figures of 6.4 vs 3.8 per 100k, 126 studies, symptom descriptions, and labeling update requirements.
- [Сбросил вес, посадил здоровье: чем опасны популярные препараты для похудения](https://regions.ru/zdorove/sbrosil-ves-posadil-zdorove-chem-opasny-populjarnye-preparaty-dlja-pohudenija) - Подтверждено по источнику regions.ru
- [Диетолог Поляков рассказал, чем опасны популярные уколы для похудения](https://vm.ru/news/1360034-dietolog-polyakov-rasskazal-chem-opasny-populyarnye-ukoly-dlya-pohudeniya) - Подтверждено по источнику vm.ru

## FAQ

### Which medications are affected by the FDA requirement?

The requirements apply to GLP-1 class drugs, including Ozempic and Wegovy (Novo Nordisk), as well as Mounjaro and Zepbound (Eli Lilly).

### Has a causal link between the drugs and vision loss been proven?

No. The FDA states that this is a potential association rather than a definitively proven cause-and-effect relationship between the drugs and the development of NAION.

### What should a patient do if their vision deteriorates?

If experiencing sudden vision loss in one eye, dark spots, blurred vision, or altered color perception, patients should seek immediate medical attention. Do not stop treatment independently without consulting a specialist.